ECR Stock Overview
Manufactures and sells basic chemicals, intermediate chemicals, and pharmaceuticals in Spain. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Ercros, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.53 |
| 52 Week High | €3.98 |
| 52 Week Low | €2.26 |
| Beta | 0.71 |
| 11 Month Change | -4.73% |
| 3 Month Change | -6.25% |
| 1 Year Change | 41.85% |
| 33 Year Change | 13.71% |
| 5 Year Change | 47.61% |
| Change since IPO | -86.83% |
Recent News & Updates
Recent updates
Estimating The Intrinsic Value Of Ercros, S.A. (BME:ECR)
Mar 02
At €2.75, Is It Time To Put Ercros, S.A. (BME:ECR) On Your Watch List?
Dec 20Here's Why Ercros (BME:ECR) Has A Meaningful Debt Burden
Nov 10Here's Why Ercros (BME:ECR) Can Manage Its Debt Responsibly
Apr 26Ercros (BME:ECR) Will Be Hoping To Turn Its Returns On Capital Around
Mar 07Why Ercros, S.A. (BME:ECR) Could Be Worth Watching
Jan 25Should You Investigate Ercros, S.A. (BME:ECR) At €3.71?
Sep 07A Look At The Fair Value Of Ercros, S.A. (BME:ECR)
Jun 09Here's Why Ercros (BME:ECR) Has A Meaningful Debt Burden
May 23Should Ercros, S.A. (BME:ECR) Be Part Of Your Dividend Portfolio?
May 05Should You Think About Buying Ercros, S.A. (BME:ECR) Now?
Mar 12Is Ercros (BME:ECR) A Future Multi-bagger?
Feb 22Here's Why Ercros (BME:ECR) Has A Meaningful Debt Burden
Feb 05
Read This Before Buying Ercros, S.A. (BME:ECR) For Its Dividend
Jan 20Is Ercros, S.A.'s (BME:ECR) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Jan 05Calculating The Intrinsic Value Of Ercros, S.A. (BME:ECR)
Dec 18Shareholders Of Ercros (BME:ECR) Must Be Happy With Their 257% Total Return
Nov 29Shareholder Returns
| ECR | ES Chemicals | ES Market | |
|---|---|---|---|
| 7D | 0% | -0.8% | 1.5% |
| 1Y | 41.9% | -2.3% | 15.4% |
Return vs Industry: ECR exceeded the Spanish Chemicals industry which returned -1.9% over the past year.
Return vs Market: ECR exceeded the Spanish Market which returned 15.9% over the past year.
Price Volatility
| ECR volatility | |
|---|---|
| ECR Average Weekly Movement | 1.8% |
| Chemicals Industry Average Movement | 4.4% |
| Market Average Movement | 3.0% |
| 10% most volatile stocks in ES Market | 5.6% |
| 10% least volatile stocks in ES Market | 0.6% |
Stable Share Price: ECR has not had significant price volatility in the past 3 months compared to the Spanish market.
Volatility Over Time: ECR's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1817 | 1,359 | Antonio Zabalza Marti | www.ercros.es |
Ercros, S.A. manufactures and sells basic chemicals, intermediate chemicals, and pharmaceuticals in Spain. It operates through three segments: Chlorine Derivatives, Intermediate Chemicals, and Pharmacy. The Chlorine Derivatives segment produces ammonia, bioplastics, caustic potash and soda, chlorine, chloroisocyanurates, dicalcium phosphate, dichloroethane, hydrochloric acid, hydrogen peroxide, potassium carbonate, PVC compounds, sodium chlorate and chlorite, sodium hypochlorite, and vinyl chloride monomers and polychloride.
Ercros, S.A. Fundamentals Summary
| ECR fundamental statistics | |
|---|---|
| Market cap | €322.31m |
| Earnings (TTM) | €14.10m |
| Revenue (TTM) | €656.52m |
22.9x
P/E Ratio0.5x
P/S RatioIs ECR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ECR income statement (TTM) | |
|---|---|
| Revenue | €656.52m |
| Cost of Revenue | €463.93m |
| Gross Profit | €192.60m |
| Other Expenses | €178.49m |
| Earnings | €14.10m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.15 |
| Gross Margin | 29.34% |
| Net Profit Margin | 2.15% |
| Debt/Equity Ratio | 42.5% |
How did ECR perform over the long term?
See historical performance and comparison